Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Denmark
Sweden
Finland
Norway
Latest
Trending
Followed

Carasent, Audiocast with teleconference, Q3'24

By Inderes10/24/2024, 6:00 AM
Carasent

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Daniel Öhman
00:00 - 04:07

Good morning, and welcome to our presentation of the third quarter. My name is Daniel Öhman. I am the CEO. And with me, I have Svein Martin Bjørnstad, our CFO, who will start with the company update. And then Svein Martin will continue with the financial update. Looking at the quarter, we have seen solid improvements in all areas, a trend which we expect to continue each quarter going forward. We have good organic growth. Almost all of that growth translates into higher EBITDA, which we are very pleased with. And as I say, that's a trend we see continuing forward. We are now on the home stretch of listing on the Nasdaq Stockholm. We aim to have the first day of trading in December, and we believe that we are now past all major obstacles, although there are some final approvals still pending. In the quarter, we have high one-time costs. And this is related to the listing, but also to the EG process and the acquisition project in Germany. There were quite high one-time costs in the quarter, which we anticipate will decrease going forward. In the report, I also highlight that I see a risk that the Volvat implementation might be slightly delayed. And to explain a bit why that's costly, I think it's worth going into it a little bit. Again, that contract has an ARR of €6 million and all that will translate to EBITDA once the contract is up and running. Furthermore, we're doing quite a lot of development work for them. And if this year, 2024, it's around 3 million NOK, that's half the price we would normally charge for that development work. So that would typically have been 6 million NOK of turnover this year. So in total, we have an EBITDA swing of 9 million. Look, once that contract is up and running, we never calculated for a majority of it to be active next year. And it won't be because it will come on clinic by clinic. We start with small clinics to ensure that everything progresses smoothly. So we might see a small delay in that contract. It may reduce some of the flexibility we had in our goals, but we still have strong belief in achieving them. But you know, you always want to have some headroom in your external goals, but at the same time, we see sales picking up. We have really good discussions with new customers. So we actually closed another significant sale this morning. So we still believe that the goals are very much realistic. And if looking at the growth, we have assigned, not implemented, the ARR of 70 million. And that translates to a 17% organic growth. In total, we are now at 23% contracted ARR growth, above our target of 20% for next year. Looking at profitability, we see the EBITDA has improved considerably. It's, however, worth noting that in the third quarter we constantly improve quarters, and we have observed significant improvements compared to last year. In total, we have achieved organic growth of €11 million in the quarter. If we add converted ARR or quarterly recurring revenue, in this case we are at €50 million. As you can also see here, last quarter, the same quarter last year, we had 2 million NOK of turnover for the Confrere company. We have now divested.

Unknown 1
04:08 - 04:08

Looking.

Daniel Öhman
04:08 - 12:03

At EBITDA-C, which is the financial metric we follow most closely internally. So growth and EBITDA are what we're looking at. We see that almost all of those 11 million NOK translate to an improved EBITDA, showing an improvement of 10 million NOK. And looking at this chart here, we have made some changes. So now we have moved HPI and Ad Opus into operations. They were previously in a separate lane together with Confrere. As we saw, we had to make a lot of improvements. So Confrere has now been divested, and HPI and Ad Opus are no longer losing large amounts of money. So now, looking at operations as such, it does not mean that we do not still need to continue to improve in that area, but we need to improve in all areas, so it doesn’t make them unique in any sense anymore. You see the growth of 17%. You see that operations have improved their EBITDA from 11 million to 18 million in the quarter, and EBITDA from 5 to 13 million. Webdoc X now incurs a running cost of 4 million each quarter. That's roughly where it will be. We're not aiming to go lower. This is where the running rate will be. We have a really efficient team making significant improvements in the development. We said it's been very stable now. We have made a lot of changes to that part of the organization and removed many consultants. We are quite happy with where that project stands at the moment. We are also lowering costs somewhat at the HQ level. I receive many questions about the situation with Millennium. So I thought it was worth discussing a bit about the potential consequences of that situation during this call. The background is that the Triathlon Union, having decided many years ago, mandated that when they switched to Millennium as their EHR system for public ARR, all private providers offering public care should also transition to the same system. And they do this to ensure that information can flow between systems. That can be accomplished in many other ways too. You can use APIs, and you can use robots. You can use the national services that are used to exchange information in Sweden, known as MPL. Most users know it as T2. So there are many other ways of accomplishing most of what they want to accomplish. All the caregivers really want to avoid transitioning to Millennium. It's a very outdated system. It fits them very poorly, and it is significantly more expensive than their current system. The price is not the major hurdle. The major hurdle is that it would significantly disrupt their operations and financial stability. It would really, really hurt them financially, and their operations would become much less efficient. Uh, where we are at is that according to the region, the first private primary care clinics should move into Millennium by the end of next year. Um, that will most likely be delayed again, but that's where they are at the moment. And that will just be a few clinics. Um, and looking at the potential outcomes, now that the private providers are trying not to get in there, we are supporting them heavily. There will be legal processes. There was quite a good case. It was a very strong case. I think it's more likely than not that they will succeed. But you never know with those types of cases. It might also become obvious, and quite likely, apparent to the region. This is not a good idea. It's really difficult for them to be a good provider to the private providers of electronic health record systems. So, the potential and the range of outcomes is what I wanted to show you. So if the region were to succeed and actually manage to resolve the legal cases, suppress all the complaints from private providers, and successfully roll it out, then it would result in a one-time churn of 15 to 25 million SEK. Um, the reason it's a range is because we cannot see what our customers are using Webdoc X for. We're not allowed to enter and see the type of patients they have, and they are only permitted to use Millennium for the patients, provided they are public patients. So, not occupational health, not insurance, not private pay patients, and so on, not vaccinations. Many might have to use double systems. That's why we have a range of scenarios from worst case to best case, and usage would be unaffected. We are not able to sell to customers at this moment who are expected to eventually transition to using Millennium. They are not purchasing a new EHR system at the moment. Then if the provider succeeds and stops this, then we would have zero chance and we would see a big increase in new sales, because at the moment we cannot sell to the region where we are the largest and most well known. So, in this scenario, we would see a big increase in new sales. And then there's the middle ground. As I said previously, many might have to use double systems. Millennium is a really bad system for our customers, so they might want to stay in Webdoc X, and then we'll transfer data into Millennium, as we do in Stockholm, where we now have the referrals going back and forth between the public system there, without the region actually opening up anything for us, we just solved it at our end, and then users would likely increase in this middle ground because then they know that they can use Webdoc X for certain patients. So these are the scenarios that we could end up in. I think it's more like not that we will succeed. And then we have a big positive scenario. In the worst case, we have roughly one year's growth that, in the worst case scenario, we would lose. The last update from June was very positive, indicating that private specialists will be excluded. They do not have to use Millennium anymore. So looking ahead, going forward, we see a really big interest in surgery. We have been developing that for quite some time now, and it will go live early next year. We can therefore start selling it now. And we're aiming to sign multiple contracts in the coming months. We believe that we have a very strong offering and have received a very positive response from potential customers. We will continue to work with efficiency; if we get a couple of percentage points more efficient in all parts every month, over a year, that translates to big improvements. And over two years, it's even bigger improvements, and we can do a lot to become more efficient. Um, I mean, most of the organization is new, either from a structural point of view or from the people, or both. So that means that there's still a lot to get in place and to become really, really efficient in all parts. And that's something we're working hard at. Um, an important area for us is cost control in this line of work.

Unknown 1
12:33 - 12:33

Work.

Daniel Öhman
12:35 - 14:24

I think the connection dropped there. Um, I hope that was an efficient use of resources. The most important part for us now is to continue cost control. There are so many things we can develop for our customers that create value, and there is no end to the number of projects we could start. So that's for you. And all of them would have a positive return on investment. But we cannot allow costs to increase in that manner. So that's why we have chosen that. We have quite a large development organization, but this is the level it should be at. And then we prioritize projects and choose the ones which create the best return on investment at a reasonable risk. We'll continue to work diligently on the financial follow-up. We have a very clear understanding of where we're heading. And the third area for us is the launch of Webdoc X. The focus remains on certifying Webdoc X for Germany. It has taken a little bit longer than expected, but that should be there in the first half of 2025. We have the first German pilots going live now. Physical clinics are actually using Webdoc X, but they're not using it for all circumstances. They are not allowed to do that yet. They are using it for part of their processes. And we're still working hard on the acquisition of a strong position in Germany. I think we are in a good place when it comes to that, but I cannot say much more about it at this point in time. With those words, I will hand over to Svein Martin Bjørnstad.

Svein Martin Bjørnstad
14:24 - 20:44

Thank you. So looking at the financials for Q3, we saw good improvement across all our metrics in the quarter. We now have a contract with an ARR base of 277 million NOK, which has grown organically by 23% over the last year. And that is, of course, boosted by these three large contracts that we have signed. That is still in the backlog, but not yet in the reported figures. And the reported recurring growth was 17%. And that is also a step up compared to what we have posted in the last few years. I would say the main driver of this is Webdoc X, where we continue to have a good pace on the sales side, and we have seen an increase in both signing new customers, new clinics and also selling to existing customer functionality. HPI is also growing rapidly, and Madrid as well had a good quarter with significant growth. We had net retention of 113%. I think it's worthwhile just recapping how we calculate that figure, because these customer groups, such as Capio, where we have many clinics, are counted as one customer in these figures. So for Webdoc X, we have signed a lot of clinics for Capio and other existing customers, and that is also a main driver of the net retention. Uh, margins are also improving. We are still at quite modest levels, but it is improving rapidly, as we see. In terms of contracted ARR growth, we see that the net upsell was 14%, churn is stable at 2%, and new customer growth was 4%. And then we have this big jump in the revenue backlog from 2 million. Um, it increased from 2 million in the same quarter last year to 17 million now. And that is driven by the contract with Volvo Pharmaceutica VGR format. And these are meant for ad queries. And these contracts will be gradually implemented next year. And that is a key contributor to our growth next year. Looking at the profitability, we see that we are improving every quarter. Um, we are now at EBITDA of 12 million and EBIT of 8 million, excluding the investments into Webdoc X, equating to an 11% margin. Additionally, alongside revenue growth, we maintain a very high focus on cost efficiencies. We have implemented several measures this year, including renegotiating prices with suppliers. We have transitioned from consultants to employees, thereby reducing costs. And we have also removed several roles during this year. And I think it's a promising signal as well for the future that we have the capacity to grow further. And when we do a budget now for next year, it's very limited roles that are even being requested by the organization. So the organization is fully on board with the strategy and the plan to keep costs flat for a long time. If you look at this slide, it shows our PNL for the quarter and year to date. I think I would like to highlight a few different figures here. Firstly, you see the gross margins improved from 80 to 85%, which is quite a big increase. That is driven by two factors. Firstly, we sold Confrere, which was dilutive, and secondly, we renegotiated costs with the hosting supplier in Norway. So it's a significant increase and it's sustainable as well. Secondly, the non-recurring expenses are high this quarter due to the costs for the EEG process and also for the Relisting. And we will incur additional costs for the Relisting in Q4 as it concludes in December. Thirdly, the figure I would like to highlight is the EBITDA minus CapEx for the group, including all costs for Webdoc X. It's also positive now at around 4 million or 6%, but it's worth noting that there are some holiday effects in there as well in Q3, as we have lower personnel expenses as people go on annual leave. And finally, the cash flow has improved significantly year over year, but it remained negative in Q3. The free cash flow. And that is primarily driven by working capital effects, where we pay out holiday bonuses to employees. And also this one-off costs as well. But in general, a good financial quarter with solid improvements in line with our targets and our plan. So with that, we can take the questions.

Operator
20:46 - 21:08

If you wish to ask a question, please dial Pound Key five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial Pound Key six on your telephone keypad. The next question comes from Frederik Nielsen from Redeye. Please go ahead.

Unknown 2
21:10 - 21:12

Good morning. Can you hear me?

Unknown 1
21:13 - 21:13

Yes.

Unknown 3
21:15 - 21:15

Good morning.

Unknown 2
21:17 - 21:35

Um, I want to start with the situation in VGR. I mean, as you mentioned, the specialists will be excluded. Does that eliminate the region success scenario, or is that included in those numbers that you presented?

Daniel Öhman
21:36 - 21:59

No, that's included in the numbers we present. I mean, we've been growing with customers all along, and also the specialists have never been able to fully transition to Millennium as they have many insurance patients, private pay, and patients from other regions. So they would always stay within Webdoc X to a very large extent.

Unknown 2
22:01 - 22:14

Okay, thanks. And now that the surgery module is more or less finished, could you remind us of the market potential for that functionality?

Svein Martin Bjørnstad
22:17 - 22:39

Ad Opus? The surgery module? Yes. We have calculated it to be around 150 million SEK. In Sweden, it's typically bigger clinics than what we normally sign. Yes, that has been our calculation.

Unknown 2
22:41 - 23:03

Okay. And given that you sound quite optimistic regarding the prospects, with customers or potential customers showing significant interest, could you elaborate a bit on your expectations? I mean, should we expect, I mean, a meaningful increase in new sales or what are your expectations?

Daniel Öhman
23:04 - 23:49

Yes, that's my expectation and that's also included in the projection for next year. I would say it's a meaningful increase in new sales. So, the study is a part of that. Even though these are typically large clinics. So, they take a bit longer to sell to, and they also take a bit longer to implement. Normally, we can sell to a small clinic and implement the system sometimes even on the same day. A large change like this. You have a lot of staff to educate. You have to do it in shifts and they have to take turns because they don’t want to lose production and so on. So, we will see that payments from new clinics will actually take some time before they start coming in. But signing contracts, I would say they are accelerating in the coming months.

Unknown 2
23:52 - 24:03

Okay. And lastly, could you elaborate a bit on why you are more successful with the semi-cold cases, as you mentioned? What's the new thing you do there?

Daniel Öhman
24:05 - 24:39

Yeah. So, I think that our sales and marketing team has done a great job. Until recently, for the past couple of years, Webdoc X was primarily sold almost exclusively through prospective customers emailing us expressing their desire to acquire Webdoc X. And then we contacted them, and now we have. Actually, we have accomplished a great deal. We are very active in marketing, using social media and direct marketing to create leads. We are very visible to our customers. I think it's important to be visible so that.

Unknown 1
24:39 - 24:39

They.

Daniel Öhman
24:39 - 25:39

They think about you and have you on top of mind. And I think there are many customers, potential customers, going around thinking that their system is quite bad, but it's a lot of work to change. Let's do that later. And those you can push, I think, to change systems earlier. So, for the sales department, we have shifted from almost exclusively fixed salaries to 30% variable pay, based on individual performance over the past month. So yeah, some of our sellers now have been receiving almost twice the normal salary settlements. So, it creates very strong incentives. We have also divided all current or potential customers among the sellers. So everyone knows who their customers are. Otherwise, it's difficult to start working with them. And we have introduced a CRM system to better understand the customers, what they're using today, and to facilitate additional sales.

Unknown 3
25:39 - 25:40

Do.

Daniel Öhman
25:40 - 26:09

Additional sales to current customers. So far this year, we've been selling to new customers a bit faster than planned. We've been slightly below plan regarding additional payments or sales to existing customers. That has really increased over the last couple of months. And I think that we are learning it's a process both for the individuals and for the organization to learn how to conduct this type of sales. And that, I think, is the key.

Unknown 2
26:11 - 26:14

Interesting. That's all from me. Thank you very much.

Unknown 3
26:14 - 26:14

Thank you very much.

Daniel Öhman
26:14 - 26:15

Frederick. Thank you very much.

Svein Martin Bjørnstad
26:15 - 26:45

Frederick. Uh, we also have some questions in the chat. The first question is from Rasmus Persson. Good morning, and congratulations on the strong quarter. Thank you. Could you clarify what you mean by 'scope' regarding the Volvo contract? Are they increasing the functionality, the number of clinics, or what are you referring to? Also, is it possible that this will lead to larger ARR from that customer?

Unknown 1
26:46 - 26:46

Yes.

Daniel Öhman
26:46 - 28:28

So what I think is, there are a couple of different things that have increased the scope. For example, they were planning to use their own billing system. Originally, they planned to use their own or an external billing system, but there is a built-in billing functionality in Mitaka, which they did not plan to use initially. But now, when I've seen how well it works together, they are planning to use our billing system instead, but then they want some additional features in that; they have also asked for a patient portal so patients can rebook their appointments and chat with the clinics and so on. We already have that functionality in Webdoc, but it is not included in my toolkit at this time. So we are also developing that. So, that's the type of thing that goes into the increased scope. It will give us some extra income from consultancy, but that's not what we look for. But that will be full-priced development. So that's better at least than what we're doing at the moment. And also, some of this functionality, we can hopefully sell to other providers, for example, the patient portal. So it will lead to better income going forward. It also will lead to more satisfied customers. So I think there are many positives in it. And it means we're talking about a couple of months' delay. So, it's no major thing. The content is still really good, but you know, being on the stock exchange, a couple of months' delay is not very fun. And it hurts.

Svein Martin Bjørnstad
28:30 - 28:38

Are there any large tenders in the market in the coming 15 months, such as the one you secured with Med Drive?

Daniel Öhman
28:38 - 29:03

Yeah. I think it's quite likely that we will see. We have signals that there might be tenders for Madre, for example. I also think that it's possible for us to secure larger contracts with both Webdoc X and Ad Opus in the coming six months. That's not a promise, but there are quite a lot of opportunities out there, so I'm hopeful.

Svein Martin Bjørnstad
29:05 - 29:22

Um, yeah. And, the final one here. This group went live in September. Will the changes to these regions affect your ability to sell into those markets in any way?

Daniel Öhman
29:22 - 29:46

So the Susa group consists of a couple of regions using Cambio. And they went live with what's not a real cloud solution, but rather one of those client-server cloud solutions from Cambio, the same system that most of them use. It does not change anything for us. These regions have very little private care and we are not focusing on them.

Svein Martin Bjørnstad
29:49 - 30:03

Great. Next one from Nicolas. Can you tell us a bit more about the development for HP? It seems like you are investing in new initiatives. What's your view on the product moving forward?

Daniel Öhman
30:04 - 32:21

Um, yeah, we're changing things from consultants to employees, so it's not new. We're not increasing costs at HPI. Um, but my view of the product is that it's a really good product. It has a strong position within occupational health, with almost all occupational health providers in Sweden using it. We have interest from Norway also on that platform. And to take that platform to Norway is not a big thing. You just need Norsk Bank. Is there? and you need, you know, the language. So it's very easy to take it to a new market. It's not like an EHR system. However, the challenge for the HP platform is that occupational health, compared to healthcare, is highly dependent on how industries are performing. Occupational health is often the first area where companies try to save money before considering staff reductions. So it's quite sensitive to downturns in the economy. So that makes it a bit harder to grow that compared to our products for the healthcare market. Uh, but still, it's a really good product. It can significantly enhance how occupational health can function, benefiting both the customers, namely their employers, and the employees. So I think it's a great product. We have big interest from both small and large occupational health care providers. The downside with that product is that they need to change somewhat how they work. And typically, I don't think we should develop solutions that require our customers to change how they work. We should allow for changes in how to work and improvements in workflows. But we also need our products to support existing workflows because otherwise, the barriers to sell are too high. So we're trying to never end up in that scenario. But sometimes you have to, and this is a big improvement, but it requires more from the customers than our new products typically do. And I would say that's why it takes a bit longer. But that being said, we are growing very rapidly in our market, which is quite challenging at the moment.

Unknown 1
32:21 - 32:22

Yeah.

Svein Martin Bjørnstad
32:22 - 32:34

And the next one is from Amelia Timby. Um, any updates on guidance for 2024, but also for 2025, given what you are currently seeing?

Daniel Öhman
32:34 - 33:13

So, no changes. As I mentioned earlier on the call, I'm a bit worried about the delays involved, which removes some of the headroom we had in the goals. I mean, you really want to have headroom in external goals so that you can beat the external goals. And that's why we want to give a heads up because we have a really good overview of where we're going. We have good cost control. We know what we're selling. We see the pace at which we're selling. So, but we still believe in our goals. We should be able to fulfill them. So, they remain unchanged.

Svein Martin Bjørnstad
33:17 - 33:24

Okay. There are no more questions in the chat.

Daniel Öhman
33:26 - 33:32

Okay, then I would just like to thank you all for listening in and hope you all have a good day. Thank you.

Continue to the webcast
Lundbeck - Præsentation af delårsrapport for Q3 2026
Language: Danish11/12/2026, 12:00 PM
H. Lundbeck A/S ventes at offentliggøre sin delårsrapport for Q3 2026 den 11. november 2026. Dagen efter, den 12. november kl. 13.00, vil Jens Høyer, Vice President & Head of Investor Relations, præsentere resultaterne og svare på spørgsmål fra publikum i et live online event.
Wirtek - Presentation of Q3 2026 Interim Report
Language: English11/12/2026, 10:00 AM
Wirtek is expected to release its Q3 2026 interim report on 11 November 2026. The next day at 11.00 CET, CEO Michael Aaen and CFO Mads Greiffenberg will present the results in a virtual live event with a Q&A session.
Rovsing - Præsentation af Interim Management Statement for Q1 2026/27
Language: Danish11/11/2026, 12:00 PM
Rovsing ventes at offentliggøre sin Interim Management Statement for Q1 2026/27 den 10. november 2026. Den 11. november kl. 13.00 vil ledelsen præsentere kvartalets tal, give en status på udviklingen i forretningen samt følge op på de seneste selskabsnyheder. Præsentationen efterfølges af en Q&A-session.
DADC - Præsentation af handelsopdatering for Q3 2026
Language: Danish11/5/2026, 8:30 AM
Du kan allerede nu tilmelde dig eventet og sende dine spørgsmål ind. Du behøver ikke at deltage live for at sende spørgsmål til præsentationen. Danish Aerospace and Defence Company (DADC) ventes at offentliggøre sin handelsopdatering for 3. kvartal 2026 den 4. november 2026. Dagen efter, den 5. november kl. 09.30, vil selskabets CEO, Thomas A.E. Andersen, præsentere resultaterne samt svare på spørgsmål i et online live-event.
Boozt AB, Audiocast, Q3'26
Language: English11/3/2026, 8:30 AM
Herman Landin Thank you and good morning to all. Welcome to our Q3 2026 presentation. So, let's turn to the first slide, please. We will follow our usual agenda. I'll take you through the highlights a…
NORDEN – Presentation of Q3 2026
Language: English10/29/2026, 9:30 AM
NORDEN is expected to release its Q3 2026 results on 29th October 2026. The same day at 10.30am, management will present the results in an online event followed by a Q&A.
Agillic – Præsentation af kvartalsrapporten for Q3 2026
Language: Danish10/22/2026, 8:00 AM
Du kan allerede nu tilmelde dig eventet og sende dine spørgsmål ind. Du behøver ikke at deltage live for at sende spørgsmål til præsentationen. Agillic offentliggør kvartalsrapporten for Q3 2026 den 22. oktober 2026. Samme dag kl. 10:00 vil selskabets CEO Christian Samsø præsentere resultaterne, gennemgå forventningerne til resten af 2026, give en opdatering på markedsforholdene og besvare spørgsmål ved et online live-event.
Nordea third-quarter results 2026
Language: English10/15/2026, 8:00 AM
Head of Investor Relations Good morning and welcome to Nordea's third-quarter 2026 results. Nordea's third-quarter 2026 results. I am your Head of Investor Relations. As usual, we will start with the…
GreenMobility - Presentation of the Q3 2026 Trading Statement
Language: English10/14/2026, 11:00 AM
GreenMobility is expected to release its Q3 2026 Trading Statement on 8 October 2026. On 14 October at 13:00 CEST, CEO Kasper Gjedsted will present the figures and answer questions in a live online event.
Rovsing – Præsentation af årsrapport 2025/26
Language: Danish9/28/2026, 9:00 AM
Rovsing ventes at offentliggøre årsrapporten for regnskabsåret 2025/26 den 25. september 2026. Den 28. september kl. 11.00 vil ledelsen præsentere årets resultater, give en status på udviklingen i forretningen samt kigge frem mod 2026/27. Præsentationen efterfølges af en Q&A-session
Danish Aerospace and Defence Company – Præsentation af H1 2026 resultater
Language: Danish8/25/2026, 8:00 AM
Danish Aerospace and Defence Company (DADC) ventes at offentliggøre selskabets rapport for H1 2026 den 24. august 2026. Dagen efter, den 25. august kl. 10.00, vil selskabets CEO, Thomas A.E. Andersen, præsentere resultaterne samt svare på spørgsmål i et online live-event.
North Media – Præsentation af regnskabet for 2. kvartal 2026
Language: Danish8/21/2026, 12:00 PM
Tilmeld dig North Media’s præsentation af regnskabet for 2. kvartal 2026 – fredag d. 21. august 2026 kl. 14.00. Se med når ledelsen i North Media gennemgår kvartalsregnskabet der offentliggøres dagen før, og hvordan første halvår af 2026 er forløbet, samt svarer på spørgsmål.
Wirtek – Presentation of Q2 2026 Interim Report
Language: English8/14/2026, 9:00 AM
Wirtek is expected to release its Q2 2026 interim report on 12 August 2026. Friday 14 August at 11.00 CEST, CEO Michael Aaen and CFO Mads Greiffenberg will present the results in a virtual live event with a Q&A session.
Boozt AB, Audiocast, Q2'26
Language: English8/14/2026, 7:30 AM
Herman Thank you. Good morning to all, and welcome to our Q2 2026 webcast. So let's turn to the first slide, the agenda for today's presentation. We will follow our usual agenda. I'll take you through…
NORDEN – Presentation of the quarterly report for Q2 2026
Language: English8/13/2026, 8:30 AM
NORDEN is set to release its quarterly report for Q2 2026 on the morning of Thursday 13 August 2026. On the same day at 10:30 AM, we are pleased to invite you to a presentation of the financial results with CEO Jan Rindbo and CFO Martin Badsted, who will also answer questions from the audience.
Sampo Oyj, Audiocast, Q2'26
Language: English8/12/2026, 7:30 AM
Mirko Hurmerinta Good morning, everyone, and welcome to Sampo Group's conference call on second quarter 2026 results. My name is Mirko Hurmerinta, the interim Head of IR at Sampo. I am joined on the c…
Nordea half-year results 2026 webcast
Language: English7/16/2026, 8:00 AM
Ilkka Good morning and welcome to Nordea's second quarter 2026 results. I am Ilkka, Head of Investor Relations. As usual, we'll start with the presentation by Group CEO Frank Vang-Jensen, followed by…
NORDEN – Presentation of the quarterly report for Q1 2026
Language: Danish5/6/2026, 8:30 AM
NORDEN is set to release their quarterly report for Q1 2026 on the morning of Wednesday 6 May 2026. On the same day at 10:30 AM, we are pleased to invite you to a presentation of the financial results with CEO Jan Rindbo and CFO Martin Badsted, who will also answer questions from the audience.
Sampo Oyj, Audiocast, Q1'26
Language: English5/6/2026, 7:30 AM
Mirko Hurmerinta Good morning, everyone, and welcome to Sampo Group's conference call on first quarter 2026 results. My name is Mirko Hurmerinta and I am the interim Head of Investor Relations at Samp…
Boozt AB, Audiocast, Q1'26
Language: English4/24/2026, 7:30 AM
Herman Good morning and welcome to our presentation of our Q1 2026 report. Let's just go to the agenda slide. We will have the usual agenda for the presentation. And I will present the highlights of t…